LAMATTINA JOHN L Insider Trading Activity

Average Profitability
2.46%
Insider Buys Quantity
2
Insider Buys Sum
$199,057.58
Insider Sells Quantity
8
Insider Sells Sum
$1.87M

Insider Activity of LAMATTINA JOHN L

According to the SEC Form 4 filings, LAMATTINA JOHN L, being in a position of

  1. director at Ligand Pharmaceuticals Incorporated,
    оver the last 12 months, has bought 0 shares, and sold 8786 shares for $2M,
    over all time since 2011-03-11, has bought 10000 shares for $98,030, and sold 30862 shares for $2.51M.

Biography of LAMATTINA JOHN L

No biography is available at this moment.

Statistics of Insider Transactions Last Year

Amount of Insider Buys and Sells by Stocks

Buys
$000
Sells
$2,003,5023100

Comparison of Insiders on Amount of Buys and Sells

2026-06-10SaleLigand Pharmaceuticals Incorporated
LGND
director
4,591
0.0232%
$250.88$1.15M+19.35%
2026-03-06SaleLigand Pharmaceuticals Incorporated
LGND
director
2,161
0.0109%
$200.76$433,842+40.9%
2025-11-07SaleLigand Pharmaceuticals Incorporated
LGND
director
2,034
0.0111%
$205.45$417,885+12.84%
2024-11-27SaleLigand Pharmaceuticals Incorporated
LGND
director
2,406
0.0129%
$123.65$297,502-4.3%
2021-05-24PurchaseImmunome, Inc.
IMNM
director
5,440
0.0482%
$18.57$101,028-16.23%
2018-09-04SaleLigand Pharmaceuticals Incorporated
LGND
director
3,335
0.0008%
$12.53$41,788-52.36%
2018-06-04SaleLigand Pharmaceuticals Incorporated
LGND
director
4,000
0.0012%
$12.53$50,120-24.41%
2018-03-05SaleLigand Pharmaceuticals Incorporated
LGND
director
3,335
0.001%
$10.12$33,750+5.38%
2017-11-17SaleLigand Pharmaceuticals Incorporated
LGND
director
4,000
0.0014%
$10.12$40,480+22%
2014-03-18SaleLigand Pharmaceuticals Incorporated
LGND
director
5,000
0.0027%
$8.97$44,850-30.47%
2011-03-11PurchaseLigand Pharmaceuticals Incorporated
LGND
director
10,000
0.0508%
$9.80$98,030+21.17%
2007-02-07SalePfizer Inc.
PFE
Senior Vice President
13,800
0.0001%
$18.35$253,230-5.04%
2005-05-06SalePfizer Inc.
PFE
Senior Vice President
39,789
0.0005%
$27.81$1.11M-5.78%
Total: 13
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.